Is Takeda Pharmaceutical Co ADR (NYSE: TAK) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

TAK belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Takeda Pharmaceutical Co ADR is $42.02B. A total of 1.1 million shares were traded on the day, compared to an average of 1.67M shares.

In the most recent transaction, TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of TAK for 8.10 per share on Jan 24 ’24. After the transaction, the 10% Owner now owns 3,755,583 company shares.


Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Takeda Pharmaceutical Co ADR pays an annual dividend of $0.32, resulting in a dividend yield of 2.38%, and it has a price to earnings (P/E) ratio of 41.82.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, TAK has a high of $16.53 and a low of $12.77.

As of this writing, TAK has an earnings estimate of $0.75 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of $0.75 per share and a lower estimate of $0.75.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. TAK’s latest balance sheet shows that the firm has $875.00B in Cash & Short Term Investments as of fiscal 2022. There were $4.35T in debt and $2.15T in liabilities at the time. Its Book Value Per Share was $15.31, while its Total Shareholder’s Equity was $5.68T.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TAK is Buy with a score of 4.50.

Most Popular

Related Posts